English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aim: The aim of this study is to evaluate the epidemiological and survival characteristics of 5634 patients with Male Genital System Cancer (MGSC) who were treated at Ege University Hospital (EUH). Materials and Methods: Surveillance, Epidemiology, and End Results (SEER) data were considered for classification and survival analysis. The data were recorded using the CANREG-4 program and transferred to SPSS program for statistical analysis. Chi-square test and linear model was used for statistical analysis, and p<0.05 value was considered significant. Results: MGSC accounts for 5.3% of all EUH cancer patients and 10.1% of all male cancers. 84.7% were located in the prostate, and 15.3% in the testis. According to the age groups prostate cancer was more frequent in males aged 60-69 years, whereas testicular cancer was more frequent in males aged 30-39 years. Among the prostate cancer patients 60.9% had localized, 20.2% had locally advanced, and 16.8% had metastatic disease. There is a linear increase in prostate cancer according to years (p<0.0001), whereas no significant increase was detected for testicular cancer. Median survival for prostate cancer was 120 months. Five and 10-year overall survival (OS) rates were 74.2% and 55.2% respectively. 5- and 10-year OS rates according to stage were 86.3% and 70%, 78.1% and 62.7%, 21.7% and 14% for localized, locally advanced and metastatic disease respectively. For testicular tumors 45.4 % were seminoma and 54.6% were non-seminoma. Five and 10-year OS rates for testicular tumors were 86.6% and 82.9% respectively. The same rates for seminomas were 95.7% and 94.2%, and for non-seminomas were 80.6% and 75.2% respectively (p<0,001). Conclusions: Among MGSC patients who were treated at EUH 84.7% were prostate and 15.3% were testicular cancers. A linear increase according to years was detected for prostate cancer. 5- and 10-year overall survival (OS) rates for prostate, and testicular cancer were 74.2% and 55.2%, and 86.6% and 82.9% respectively. Ten-year OS rate for seminomas was 94.2% whereas it decreased to 94.2% for non-seminomas.

Ege Üniversitesi Hastanesinde erkek genital sistem kanserlerinin epidemiyolojik ve genel sağ kalım özellikleri